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Abstract Mitochondriopathies often present clinically as multisystemic disorders of primarily
high-energy consuming organs. Assembly, turnover, and surveillance of mitochondrial proteins are
essential for mitochondrial function and a key task of AAA family members of metalloproteases.
We identified a homozygous mutation in the nuclear encoded mitochondrial escape 1-like 1 gene
YME1L1, member of the AAA protease family, as a cause of a novel mitochondriopathy in a
consanguineous pedigree of Saudi Arabian descent. The homozygous missense mutation, located
in a highly conserved region in the mitochondrial pre-sequence, inhibits cleavage of YME1L1 by the
mitochondrial processing peptidase, which culminates in the rapid degradation of YME1L1
precursor protein. Impaired YME1L1 function causes a proliferation defect and mitochondrial
network fragmentation due to abnormal processing of OPA1. Our results identify mutations in
YME1L1 as a cause of a mitochondriopathy with optic nerve atrophy highlighting the importance of
YME1L1 for mitochondrial functionality in humans.
DOI: 10.7554/eLife.16078.001
Introduction
Mitochondriopathies often present as multisystemic diseases and can be caused by mutations in
nuclear or mitochondrial DNA-encoded genes (Nunnari, 2012). Here, we report a novel form of
mitochondriopathy with infantile-onset developmental delay, muscle weakness, ataxia, and optic
nerve atrophy caused by a homozygous mutation in the yeast mitochondrial escape 1-like 1 gene
YME1L1.
YME1L1 was first identified in yeast, in a screen for gene products that elevate the rate of mito-
chondrial DNA migration to the nucleus (Campbell et al., 1994; Thorsness et al., 1993). The lack of
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yme1 impairs respiratory growth of yeast highlighting its important function in mitochondrial mainte-
nance (Nakai et al., 1995; Pearce and Sherman, 1995). YME1L1, a member of the AAA family of
ATPases (ATPases associated with a variety of cell activities), is a nuclear genome-encoded ATP-
dependent metalloprotease embedded in the inner mitochondrial membrane (IM), with its protease
domain facing the intermembrane space (IMS) (also termed i-AAA protease) (Leonhard et al., 1996;
Shah et al., 2000; Weber et al., 1996). Its import into mitochondria is accompanied by proteolytic
processing via the mitochondrial processing peptidase (MPP), which cleaves off the mitochondrial
targeting sequence (MTS) (Rainey et al., 2006). The mature protein assembles into a homo-oligo-
meric complex within the IM (Leonhard et al., 1996; Van Dyck and Langer, 1999). YME1L1
degrades both IMS and IM proteins such as lipid transfer proteins (Potting et al., 2013), compo-
nents of protein translocases of the IM (Baker et al., 2012; Rainbolt et al., 2015), and the dynamin-
like GTPase optic atrophy 1 (OPA1) (Anand et al., 2014; Rainbolt et al., 2015; van der Bliek and
Koehler, 2003).
The OPA1 gene (MIM*605290), mutated in dominant optic atrophy (Delettre et al., 2000), enco-
des a mediator of mitochondrial fusion that also orchestrates mitochondrial cristae morphogenesis
(Cipolat et al., 2004; Frezza et al., 2006; Olichon et al., 2003). OPA1 is processed by two pepti-
dases in the IM, YME1L1 and OMA1 (overlapping with the m-AAA protease 1 homolog), which
thereby balance fusion and fission of mitochondria (MacVicar and Langer, 2016). Long OPA1 forms
(L-OPA1) carry out mitochondrial fusion, while short forms (S-OPA1) are dispensable for fusion but
contribute to mitochondrial fission when accumulated (Anand et al., 2014; Ehses et al., 2009;
Griparic et al., 2007; Head et al., 2009; Song et al., 2007). Loss of YME1L1 accelerates OMA1-
dependent L-OPA1 cleavage, resulting in S-OPA1 accumulation, increased mitochondrial fission, and
mitochondrial network fragmentation (Anand et al., 2014; Wai et al., 2015). Despite previous
attempts to link YME1L1 to human disease (Coenen et al., 2005), its physiological role in humans
remains to be elucidated.
Results and discussion
Homozygous YME1L1 missense mutation causes mitochondriopathy
We report for the first time that patients with a homozygous mutation in the YME1L1 gene develop
an infantile-onset mitochondriopathy. Four affected children of healthy, consanguineous parents of
Saudi Arabian descent were born at term without complications and with normal anthropometric
data (Figure 1A). Medical history gave no indication for perinatal brain damage as a cause for the
reported patient phenotypes. All four patients presented with intellectual disability, motor develop-
mental delay, expressive speech delay, optic nerve atrophy associated with visual impairment, hear-
ing impairment, but no facial dysmorphism (Figure 1B, Table 1). Inconsistent features were
microcephaly (II.9, II.11) or macrocephaly (II.5), ataxia (II.5, II.8, II.9), hyperkinesia (II.9), and athetotic
and stereotypic movements (II.11). Cranial MRI revealed leukoencephalopathy in all patients and
signs of brain atrophy in patients II.9 and II.11 (Figure 1C). Lactate levels and lactate/pyruvate ratios
were elevated in blood and/or cerebrospinal fluid (CSF) of three patients as indicators of a mitochon-
driopathy, while alanine levels were normal in blood and cerebrospinal fluid samples. Analysis of a
muscle biopsy specimen from patient II.5 revealed mitochondria with altered cristae morphology
(so-called ‘parking lots’) and paracristalline inclusions as well as a neurogenic pattern with grouped
fibers indicating denervation, but no conspicuous ragged red fibers in the Gomori trichrome staining
(Figure 1D). Results of chromosome analysis, mitochondrial DNA sequencing and genetic testing for
fragile X syndrome, Nijmegen breakage syndrome, and ataxia teleangiectasia were normal. Similarly,
biochemical analyses gave no indication for adrenoleukodystrophy, GM1/GM2 gangliosidoses,
Sandhoff disease, Tay-Sachs disease, Gaucher disease, Fabry disease, Krabbe disease, Mucopolysac-
charidosis type IVB, neuronal ceroid-lipofuscinoses 1 and 2, and congenital disorder of glycosylation
(CDG) syndrome (data not shown).
To identify the genetic basis of the disease, we performed whole-exome sequencing (WES) fol-
lowed by Sanger sequencing and bioinformatic analysis. We thereby identified a homozygous mis-
sense mutation in a highly conserved region of the YME1L1 gene in the affected children (c.616C>T,
NM_014263; chr10:27425300; GRCh 38.5, raw data available: sequence reads archive (SDA) acces-
sion no. SRP073309) that segregates with the phenotype in the index family. We did not detect
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Figure 1. Phenotype and genotype of patients with YME1L1 mitochondriopathy. (A, B) The four affected patients are children of healthy,
consanguineous parents of Saudi Arabian decent (□ male; ○ female; à unknown gender; deceased; heterozygous, clinically not affected; ./&
Figure 1 continued on next page
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mutations in other genes linked previously to neurologic diseases. (De Michele et al., 1998;
Hazan et al., 1994; Warnecke et al., 2007). The YME1L1 gene mutation c.616C>T causes the
exchange of highly conserved hydrophilic arginine to hydrophobic tryptophan (p.R149W,
NP_055078) within the N-terminal MTS (Figure 1E–G). YME1L1R149W was below detection levels or
profoundly reduced in patient whole cell lysates and in mitochondrial enriched fractions of patient
fibroblasts, while mRNA levels remain unaltered (Figure 1H,I, Figure 1–source data 1, Figure 1–fig-
ure supplement 1). These results identify a disease-causing mutation in arginine 149 of YME1L1,
which impairs protein accumulation.
YME1L1R149W abrogates maturation of YME1L1 upon import into
mitochondria
The affected amino acid residue arginine 149 is present within a predicted mitochondrial targeting
sequence of YME1L1 and may affect targeting of the mutant protein to mitochondria. We therefore
transiently expressed YME1L1 and YME1L1R149W in YME1L1-/- HeLa cells generated by CRISPR/
Cas9-mediated genome editing (Figure 2A). Both YME1L1 and YME1L1R149W co-localized with the
mitochondrial marker protein ATPase subunit ß, demonstrating mitochondrial targeting of the
mutant protein. Consistently, inhibition of the proteasome did not stabilize mutant YME1L1
(Figure 2B), suggesting that reduced levels of YME1L1R149W are not caused by proteasomal degra-
dation of non-imported YME1L1 precursor proteins. We therefore excluded a degradation of mutant
YME1L1R149W via the proteasome.
Nuclear-encoded YME1L1 requires cleavage of the MTS from premature YME1L1 (~80 kDa) upon
import into mitochondria to give rise to the mature protein (~63 kDa), which is able to assemble into
a homooligomeric proteolytic complex in the IM (Graef et al., 2007; Stiburek et al., 2012;
Van Dyck and Langer, 1999). MTS cleavage of YME1L1 precursor is bioinformatically predicted to
be mediated by MPP (NM_014263; Mitoprot) (Claros and Vincens, 1996). Since the identified
human mutation affects an arginine and such residues are known to function as MPP recognition and
cleavage sites (Niidome et al., 1994), we asked whether arginine 149 is part of the MPP cleavage
site in YME1L1. We mutated various arginine residues in the N-terminal region of YME1L1 and ana-
lyzed maturation of corresponding YME1L1 variants synthesized in a cell-free expression system
using recombinant MPP (Figure 2C). YME1L1 was converted by MPP in its mature form (Figure 2C).
Mutation of arginine at position 149 abrogated MPP-mediated processing of YME1L1, suggesting
Figure 1 continued
homozygous, affected; , consanguineous marriage). (C) Cranial MRIs reveal hyperintense changes (arrows) as a sign for leucencephalopathy, and
cerebral atrophy (FLAIR, axial images). (D) Histological analysis of patient II.5 muscle biopsy specimen, from left to right: Gomori trichrome stain for
muscle fibers revealed no conspicuous ragged red fibers indicative of a mitochondriopathy. Succinate dehydrogenase (SDH) and neuron specific
enolase (NSE) staining revealed a neurogenic pattern with grouped fibers indicating denervation (magnification 200x). Electron microscopy (EM)
revealed paracristalline inclusions (arrow) and altered cristae structure (“parking lots”, magnification 15,000x). (E) Whole exome sequencing discovered
the homozygous mutation c.616C>T in exon 5 of the YME1L1 gene (NM_014263), localized at position 149 of the YME1L1 protein, and leading to an
amino acid exchange of arginine to tryptophan in the mitochondrial targeting site (MTS; p.R149W, NP_055078). YME1L1 contains highly conserved
domains: MTS, transmembrane domain (TM), ATPase domain (AAA+), motif of metalloprotease (Zinc) activity (HESGH). (F) Electropherogram depicting
homozygous missense mutation in patient II.5, which is heterozygous in the father. (G) The mutation lies within a protein region, highly conserved
throughout different species. (H) YME1L1 mRNA levels do not differ between patient and control primary human adult fibroblasts (Co, Control; II.5,
patient II.5; ns, not significant; one-way ANOVA; p=0.2314; n=6 ) (I) Steady state levels of YME1L1 are below detection levels or profoundly reduced in
cell lysates of patient II.5 YME1L1R149W; Yme1l1 knockout mouse fibroblasts serve as negative controls. YME1L1 protein levels in mitchondrial
compartment fractions can be found Figure 1—figure supplement 1 (HAF, primary human adult fibroblasts; ACF, immortalized murine adult cardiac
fibroblasts; MEF, immortalized murine embryonic fibroblast; Co, Control; II.5, patient II.5; WT, wild type; KO, Yme1l1 knockout, n=5).
DOI: 10.7554/eLife.16078.002
The following source data and figure supplement are available for figure 1:
Source data 1. Raw data Graph 1H.
DOI: 10.7554/eLife.16078.003
Figure supplement 1. (I) YME1L1R149W signal is barely detectable in total cell lysates (T), significantly reduced in the mitochondrial (M) but not present
in the cytosolic (C) fraction of patient primary human adult fibroblasts (Co, Control; II.5, patient II.5; SDHA, succinate dehydrogenase; LDHA, lactate
dehydrogenase; n=3).
DOI: 10.7554/eLife.16078.004
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Table 1. YME1L1 mitochondriopathy phenotype.
Pedigree ID (gender) II.5 (f) II.8 (f) II.9 (m) II.11 (f)
Age at last assessment (y) 15.8 12.3 10.3 5.2
Category Feature HPO
Inheritance
AR AR AR AR
Growth
Height Short stature
SD;%
0004322 +
-2.19; 1
+
-2.09; 2
+
-1.89; 3
-
0.38; 35
Weight Low weight
SD;%
0004325 +
-2.8; <1
-
-1.18; 12
-
0.07; 53
-
-1.35; 12
Neonatal period
Neonatal asphyxia 0012768 - - - +
Head and Neck
Head Microcephaly 0000252 - - + +
Macrocephaly 0000256 + - - -
Face Midface retrusion 0011800 - - + +
Congenital facial diplegia 0007188 + - - +
Ears Hearing impairment 0000365 - + + +
Sensorineural hearing impairment 0000407 n.a. n.a. + +
Macrotia 0000400 - + + -
Eyes Pigmentary retinopathy 0000580 + - - -
Optic nerve hypoplasia 0000609 + + + +
Cherry red spot of the macula 0010729 - - - +
Strabismus 0000486 - - + +
Hypermetropia 0000540 - - - +
Myopia 0000545 + + + -
Amblyopia 0000646 - + + +
Abnormality of visual evoked potentials 0000649 n.a. - + +
Abdomen
Gastro-intestinal Constipation (in infancy) 0002019 + n.a. + +
Spleen Splenomegaly 0001744 + - + -
Skeletal
Feet Bilateral talipes equinovarus 0001776 - - - +
Muscle, soft tissue
Increased variability in muscle fiber diameter 0003557 + n.a. n.a. n.a.
Neurologic
CNS Hypotonia, neonatal, generalized 0008935 - - - +
Infantile muscular hypotonia 0008947 - - - +
Global developmental delay (onset, months) 0001263 + + + + (6)
Motor delay 0001270 + + + +
Gait apraxia 0010521 - - - +
Athetosis 0002305 - - - +
Intellectual disability, moderate; (IQ) 0002342 + (48) n.a. n.a. + (39)
Incomprehensible speech 0002546 n.a. - - +
Poor speech 0002465 n.a. - + -
Absent speech 0001344 - + - -
Table 1 continued on next page
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that amino acid 151 forms the N-terminal amino acid of mature YME1L1. Replacement of arginine
149 by tryptophan similarly abolished maturation of YME1L1 by MPP in vitro (Figure 2D).
YME1L1R149W undergoes rapid proteolysis
Grossly reduced YME1L1 protein levels coinciding with unaltered mRNA levels indicate a post-tran-
scriptional mechanism responsible for the reduction of YME1L1R149W. Stabilization of the precursor
form of YME1L1 by abolishing the MPP recognition site may allow another peptidase to cleave
YME1L1. To identify the latter mechanism, we screened candidate mitochondrial proteases for their
effect on YME1L1 and YME1L1R149W stably expressed in HEK293T cells, but could not detect a dif-
ference in YME1L1/YME1L1R149W level upon depletion of individual proteases (data not shown).
However, by preventing the proteolytic activity of YME1L1 upon ectopic expression of the domi-
nant-negative YME1L1E381Q, harboring a point mutation in the ATPase domain, we were able to sta-
bilize not only the known YME1L1 substrate PRELID1 (Potting et al., 2013) but also observed
accumulation of both the precursor and mature forms of YME1L1 (Figure 3A). The mature form of
YME1L1 remained stable in cells harboring YME1L1E381Q upon further incubation in the presence of
cycloheximide, while ectopic expression of the wild type variant resulted in significantly lower levels
of YME1L1 and reduced stability (Figure 3A). These observations point to an auto-catalytic degrada-
tion of YME1L1R149W. We therefore combined the dominant negative mutation E381Q with the path-
ogenic mutation R149W in YME1L1 in cis and examined the stability of this variant (Figure 3A). We
observed an accumulation of mature YME1L1R149W/E381Q upon ectopic expression in HEK293T cells
(Figure 3A). Both mature YME1L1R149W/E381Q and larger forms with a similar size to the precursor
form of YME1L1 accumulated in these cells. Stabilization of the precursor form of YME1L1 in these
cells may allow another peptidase to cleave YME1L1 resulting in the accumulation of slightly smaller
forms of YME1L1. These results suggest that YME1L1 mediates degradation of mutant
YME1L1R149W, which accumulates in the precursor form due to the mutation of the MPP cleavage
site and thus is likely recognized as a misfolded protein in the IM. As the mutant YME1L1 variants
were expressed in wild type HEK293T cells, we cannot distinguish whether degradation of
YME1L1R149W occurs intramolecularly and/or by endogenous YME1L1 under these experimental con-
ditions. However, the lack of wild-type YME1L1 in patient cells with homozygous YME1L1 mutations
together with our ectopic expression studies argue for auto-catalytic degradation of YME1L1R149W.
Table 1 continued
Pedigree ID (gender) II.5 (f) II.8 (f) II.9 (m) II.11 (f)
Seizures (onset, months) 0001250 - - - + (6)
Dysmetria 0001310 + + + -
Ataxia 0001251 + + + -
Brain atrophy 0012444 - - - +
Ventriculomegaly 0002119 - - - +
Delayed CNS myelination 0002188 + - - -
Abnormality of the cerebral white matter 0002500 + + + +
Abnormality of the basal ganglia 0002134 - - + -
Cerebellar hypoplasia (progressive) 0001321 + - - +
EEG with focal sharp waves 0011196 n.a. - + -
Abnormal auditory evoked potentials 0006958 n.a. n.a. + +
PNS Decreased sensory nerve conduction velocity 0003448 - + n.a. -
Behavioural Psychiatric Hyperactivity 0000752 - + - -
Attention deficit hyperactivity disorder 0007018 - - - +
Stereotypical body rocking 0012172 - - - +
Laboratory anomalies
Mildly elevated creatine phosphokinase 0008180 - - - +
DOI: 10.7554/eLife.16078.005
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Figure 2. Mutation of arginine 149 impairs maturation of YME1L1 by MPP upon import into mitochondria. (A) YME1L1R149W is targeted to mitochondria.
HeLa cells were transiently transfected with wild-type YME1L1, YME1L1R149W or the empty vector (EV) as control. Cells were analyzed by indirect
immunofluorescence and co-localization of the immunofluorescent signals of antibodies against YME1L1 and ATP Synthase subunit beta (ATPase-ß)
(WT, Wildtype; YME1L1-/-, Knockout; EV, empty vector; YME1L1R149W, patient mutation; Scale bar 10 mM). (B) Inhibition of the proteasome with MG132
(20 mM, 18 h) does not stabilize precursor or mature YME1L1 in Flp-In T-Rex HEK293T cells expressing YME1L1 or YME1L1 mutant variants: R149W,
E381Q or R149W/E381Q. P4D1 antibodies were used as a control for ubiquitin accumulation and proteasome inhibition. (R149W, patient
mutation; E381Q, dominant negative mutation of ATPase domain; R149W/E381Q, double mutant; *, unspecific signal; p, premature; m, mature; PoS,
Ponceau staining; n=2). (C) Maturation of YME1L1 is mediated by mitochondrial processing peptidase (MPP) and impaired upon mutation of arginine
149. After site-directed mutagenesis of N-terminal arginine residues in YME1L1, the mutant proteins were expressed in a cell-free system and
processing by recombinant MPP was examined (WT, wild type YME1L1; p, premature m, mature, n=2–3). (D) Cell-free MPP cleavage-assay: MPP can
cleave YME1L1 but not YME1L1R149W from the premature to its mature form (min, minutes; p, premature; m, mature; YME1L1R149W,
patient mutation; n=3).
DOI: 10.7554/eLife.16078.006
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Figure 3. Mutation of arginine 149 destabilizes YME1L1 but retains residual YME1L activity. (A) Stability of YME1L1 or YME1L1 mutant variants (R149W,
E381Q and R149W/E381Q) expressed in Flp-In T-Rex HEK293T cells. The dominant negative E381Q mutation in the ATPase domain of YME1L1
prevents degradation of YME1L1R149W (E381Q, dominant negative mutation of ATPase domain; R149W, patient mutation; R149W/E381Q, double
mutant; CHX, cycloheximide; h, hours; p, premature; m, mature; SDHA, succinate dehydrogenase; n=2). (B) Homozygous mutation in YME1L1 results in
an accumulation of PRELID1 in the human patient. Yme1l1 knockout mouse fibroblasts serve as positive controls to demonstrate impaired proteolysis of
PRELID1 (HAF, human adult primary fibroblasts; ACF, immortalized murine adult cardiac fibroblasts; MEF, immortalized murine embryonic
fibroblast; Co, Control; II.5, patient; WT, wild type; KO, knockout; n=5). (C) Mutation of arginine 149 of YME1L1 impairs processing of OPA1 with a
decrease of short OPA1 form d levels. The formation of OPA1 form d indicates residual YME1L1 activity in human patient fibroblasts (immort. HAF,
immortalized human adult fibroblasts; ACF, immortalized murine adult cardiac fibroblasts; MEF, immortalized murine embryonic fibroblast; Co, Control;
II.5, patient; WT, wild type; KO, knockout; n=6). The schematic diagram illustrates the proteolytic processing of OPA1 by YME1L1 on processing site 2
(S2) and OMA1 on processing site 1 (S1). The presence of long OPA1 forms (L-OPA1) is required for the maintenance of mitochondrial inner membrane
fusion, whereas accumulation of short OPA1 forms (S-OPA1) is associated with accelerated fission. (D) Mitochondria-enriched membrane fractions from
Flp-In T-Rex HEK293T cells expressing YME1L1 or YME1L1 mutant variants (R149W, E381Q and R149W/E381Q) were solubilized in digitonin and
Figure 3 continued on next page
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Impaired proteolysis by YME1L1R149W
To confirm a functional impairment of YME1L1R149W, we analyzed the effect of YME1L1R149W on two
substrate proteins, the protein of relevant evolutionary and lymphoid interest (PRELID1) and OPA1,
in patient-derived skin fibroblasts. PRELID1, a lipid transfer protein for phosphatidic acid in the IMS,
is constitutively degraded by YME1L1 (Potting et al., 2013). PRELID1 accumulated in primary
human fibroblasts (HAF) of patient II.5 when compared to controls (Figure 3B), consistent with the
low levels of YME1L1R149W present in mitochondria (Figure 1I, Figure 1–figure supplement 1).
Deletion of murine Yme1l1 leads to accelerated processing of L-OPA1 by OMA1 (Anand et al.,
2014; Rainbolt et al., 2016) and drives mitochondrial fragmentation in vitro (Baker et al., 2014)
and in vivo (Korwitz et al., 2016; Wai et al., 2015). We similarly identified an altered cleavage pat-
tern of OPA1 in patient cells, albeit more modestly than in knockout mouse cells (Figure 3C).
This suggests that YME1L1R149W retains proteolytic activity. As proteolysis by YME1L1 depends
on its oligomerization, we examined in further experiments the assembly of YME1L1R149W expressed
in HEK293 cells by sucrose gradient centrifugation (Figure 3D). To allow detection of YME1L1R149W
precursor forms and impair its degradation, we also examined the assembly of YME1L1R149W/E381Q
expressed in HEK293 cells. Similar to YME1L1, the mutant variants of YME1L1 were recovered in
protein complexes of ~2 MDa (Figure 3D). Notably, we also observed assembly of the precursor
form of YME1L1R149W/E381Q, demonstrating that the disease-causing mutation R149W does not
impair the formation of the i-AAA protease complex. Thus, assembled YME1L1R149W precursor forms
may explain the residual activity of YME1L1 in patient fibroblasts (Figure 3E). Alternatively, and not
mutually exclusive, low levels of mature YME1L1R149W may maintain residual proteolytic activity in
the patient system.
Together, we conclude that YME1L1R149W is a hypomorphic allele that retains partial YME1L1
activity, which reconciles the embryonic lethality (Wai et al., 2015) of Yme1l1 knockout mice with
the milder phenotype in our patients with a homozygous YME1L1 missense mutation.
YME1L1R149W causes mitochondrial fragmentation
Given the role of unbalanced mitochondrial dynamics in neurodegenerative diseases (Burte´ et al.,
2015) and the observed, impaired OPA1 processing, we focused our attention on mitochondrial
morphology in patient fibroblasts. We detected an increase in shortened and fragmented mitochon-
drial networks in HAF of patient II.5 relative to a control (Figure 4A,B, Videos 1–4, Figure 4–source
data 1), consistent with the more severe fragmentation phenotype in Yme1l1 KO mouse fibroblasts
(Anand et al., 2014). We therefore transiently expressed human YME1L1R149W and YME1L1 in
murine adult cardiac Yme1l1-/-fibroblasts (Wai et al., 2015) and observed that human YME1L1 but
not YME1L1R149W was able to complement mitochondrial fragmentation. Of note, the human mutant
variant was still able to partially tubulate mitochondria (Figure 4C,D, Figure 4–source data 1), con-
sistent with the notion that YME1L1R149W retains residual function.
YME1L1R149W impairs cell proliferation
To further address the pathophysiological mechanism underlying the neurological phenotype in
humans, we analyzed proliferation and apoptosis of HAF. Proliferation of patient II.5 fibroblasts was
significantly reduced compared to those of healthy controls, while the level of induced apoptotic cell
death remained unaffected (Figure 5A–C, Figure 5–source data 1, Figure 5–source data 1, Fig-
ure 5–source data 1). Analysis of the respiratory chain in patient fibroblasts revealed the specific
enzymatic activities to be within the normal physiological range and subunit levels to be unaltered
(Figure 5D,E), consistent with the observation in Yme1l1–depleted hearts (Wai et al., 2015).
Figure 3 continued
analyzed by sucrose gradient centrifugation. Fractions were collected and separated on SDS-PAGE for immunoblotting to detect high MW complexes
of YME1L1. HSP60 complexes were used as a control (M, mitochondrial input, P, S, pellet and supernatant fraction after solubilization; HSP60, heat
shock protein 60; E381Q, dominant negative mutation of ATPase domain; R149W, patient mutation; R149W/E381Q, double mutant). (E) Premature
YME1L1/ YME1L1R149W is imported into the mitochondrial matrix via translocons of the outer mitochondrial membrane (TOMM) and inner
mitochondrial membrane (TIMM). Here, MPP binds and cleaves the N-terminal mitochondrial targeting site (MTS) from premature YME1L1 but not
YME1L1R149W, which then allows the mature and premature YME1L1R149W protein to assemble as proteolytic complex.
DOI: 10.7554/eLife.16078.007
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However, the reduced steady state levels of various mitochondrial compartment markers in patient
cells indicate a general reduction of mitochondrial mass in YME1L1R149W cells (Figure 5E,
Figure 5F).
Figure 4. YME1L1R149W causes mitochondrial fragmentation. (A, B) YME1L1R149W causes fragmentation (fragmentation or short tubules) of
mitochondrial networks in patient fibroblasts (Co, Control, II.5, patient II.5; one-way ANOVA; n=150–200 cells; 4 replicates; scale bar 10 mm). (C) Co-
transfection of mitochondrial GFP and human YME1L1/ YME1L1R149W protein in WT and Yme1l1-/- MEFs revealed that YME1L1 but not YME1L1R149Wcan
rescue mitochondrial fragmentation in Yme1l1-/- MEFs and (D) increases the number of cells with tubular networks. Expression of YME1L1R149W partially
rescues the fragmentation phenotype. In WT MEFs, YME1L1R149W expression results in only a mild, but not significant decline of cells with a tubular
mitochondrial network (WT, wildtype; Yme1l1-/-, Yme1l1 Knockout; two-way ANOVA; n=3; scale bar 10 mm; **p<0.01; ***p<0.001; ****p<0.0001).
DOI: 10.7554/eLife.16078.008
The following source data is available for figure 4:
Source data 1. Raw data Graph 4B.
DOI: 10.7554/eLife.16078.009
Source data 2. Raw data Graph 4D.
DOI: 10.7554/eLife.16078.010
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Here we report a new form of infantile-onset mitochondriopathy caused by a homozygous muta-
tion in the YME1L1 gene. Patients suffer from severe intellectual disability, muscular impairments,
and optic nerve atrophy. In contrast to complete gene deletion in the mouse (Wai et al., 2015), the
homozygous c.616C<T missense mutation is compatible with life, likely owing to the residual func-
tion of YME1L1R149W. We demonstrate that the missense mutation affects the MPP processing site
and impairs YME1L1 maturation, leading to its rapid degradation. We further show that the
YME1L1R149W leads to a proliferation defect, abnormal OPA1 processing and mitochondrial frag-
mentation. Since fusion and fission of mitochondria are essential to preserve cellular functions, it is
conceivable that defects in these processes, contribute to the patient phenotype in a cell-type spe-
cific manner. With our findings, we reveal an important role of YME1L1 for the maintenance of mito-
chondrial morphology in humans and link a loss of YME1L1 function to disease. YME1L1 thereby
joins other members of the AAA family of ATPases that have already been linked to neurologic dis-
ease, such as spastin (SPG4, MIM*6042779 and paraplegin (SPG7, MIM*602783) gene, and in the
gene encoding the YME1L1 substrate optic atrophy 1 (OPA1, MIM*605290) (De Michele et al.,
1998; Hazan et al., 1994; Nielsen et al., 1997; Warnecke et al., 2007). Future studies on further
patients are required to determine the full phenotype spectrum associated with YME1L1 gene
mutations.
Video 1. Three dimensional rendering of mitochondrial
structure of a control fibroblast. MitoTracker Deep Red-
mitochondria; DAPI-nucleus.
DOI: 10.7554/eLife.16078.011
Video 2. Three dimensional rendering of mitochondrial
structure of a patient II.5 fibroblast. MitoTracker Deep
Red- mitochondria; DAPI-nucleus.
DOI: 10.7554/eLife.16078.012
Video 3. Mitochondrial dynamics in a control
fibroblast. MitoTracker Green-mitochondria, live cell
imaging.
DOI: 10.7554/eLife.16078.013
Video 4. Mitochondrial dynamics in a patient II.5
fibroblast. MitoTracker Green-mitochondria, live cell
imaging.
DOI: 10.7554/eLife.16078.014
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Figure 5. YME1L1 mutation impairs fibroblast cell growth and proliferation. (A) Significant reduction of cell culture growth (y-axis scale *104) and (B)
proliferation of patient primary human adult fibroblasts after 120h under culture conditions (Co, Control; II.5, patient II.5; one-way ANOVA; ***p<0.001;
****p<0.0001; n=5 ). (C) No increase in apoptosis-sensitivity upon 2 mM staurosporine (STS) treatment in patient HAF after 6h (SDS-PAGE for cleaved
PARP level (cPARP) (Co, Control; II.5, patient II.5; one-way ANOVA; p6h = 0.4283; n=3; ). (D) Normal respiratory chain subunit activity in patient HAF (U,
units; mU, milli U; CS, Citrate synthase). (E) Cytochrome c oxidase subunit 4 (COX4) and NADH ubiquinone oxidoreductase 1 beta subcomplex 6
(NDUFB6) protein levels were not elevated in patient fibroblasts (Co, Control; II.5, patient II.5; n=3). (F) Decreased levels of mitochondrial compartment
markers TOMM20 (translocon of outer mitochondrial membrane 20) for the outer membrane (OM), Cytochrome c for the intermembrane space (IMS),
SDHA (succinate dehydrogenase) for the inner membrane (IM), and Cyclophilin D for the matrix in whole cell lysates of patient II.5 (Co, Control; II.5,
patient II.5; n=3).
DOI: 10.7554/eLife.16078.015
The following source data is available for figure 5:
Source data 1. Raw data Graph 5A.
DOI: 10.7554/eLife.16078.016
Source data 2. Raw data Graph 5B.
DOI: 10.7554/eLife.16078.017
Source data 3. Raw data Graph 5C.
DOI: 10.7554/eLife.16078.018
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Material and methods
Subjects
Informed consent was obtained from the parents of the patients for the molecular genetic analysis,
the publication of clinical data, photos, magnetic resonance images (MRI), and studies on fibroblasts.
The human study was approved by the local ethics committee of the Charite´ (approval no. EA1/212/
08).
Genetic analyses
Homozygosity linkage intervals (chr10:24,333,063–49,978,774, LOD=2.533) with LOD>2 and length
>1 Mb were identified using the Affymetrix SNP array 6.0. For whole exome sequencing, 1 mg geno-
mic DNA extracted from peripheral blood was enriched by Agilent SureSelect Human All Exon
enrichment kit version 3 and deep-sequenced by Illumina Hiseq2000 sequencer in a 101 bp single-
end mode. The output sequences amounted to 12 Gb and >94% of the exon-coding regions were
covered by at least 20 folds. The data analysis pipeline considered linkage interval, pathogenicity of
variants, allele frequency in polymorphism databases (1000Genome, ESP, and an in-house database
including 868 individual exomes of Middle East origin), functional involvement of specific genes,
thus resulting in the identification of a homozygous YME1L1 gene mutation (chr10p12.1)
(Najmabadi et al., 2011). We confirmed the absence of homozygous deleterious variants (missense,
nonsense, frameshift, splice site change) in YME1L1 in the NHLBI Exome Sequencing Project (ESP,
http://evs.gs.washington.edu/EVS/; ExAC 0.3 http://exac.broadinstitute.org/), the 1000 Genome
database (http://www.1000genomes.org/), the dbSNP138 (http://www.ncbi.nlm.nih.gov/SNP/), and
our in-house 898 Middle East origin exome database. The raw data is available under the sequence
reads archive (SDA) accession no. SRP073309.
Sanger sequencing of the YME1L1 gene (NM_014263, GRCh 38.5) confirmed the mutation in the
patients and established the genotype in the other family members and in additional families.
Mouse and human fibroblasts
HAF were established from skin biopsies derived from patient II.5 and unrelated controls (Co1-3).
MEF and adult cardiac fibroblasts (ACF) were derived from Yme1l1 mutant mice (Yme1l1loxP/loxP) as
described previously (Anand et al., 2014; Wai et al., 2015; Yao and Shoubridge, 1999). HAF,
MEF, and ACF were cultured in high glucose Dulbecco’s modified Eagle’s medium (Gibco, Darm-
stadt, Germany) supplemented with 15%, 10%, and 10% fetal bovine serum (FBS, Biochrome, Berlin,
Germany; Life Technologies; Carlsbad, California), respectively, and 1% penicillin-streptomycin
(Sigma Aldrich; St. Louis, Missouri). Fibroblasts were immortalized by stable expression of hTERT
and E7 (Zhu et al., 1998).
Generation of YME1L1-/- HeLa cells
YME1L1 KO cells were generated using the CRISPR/Cas9 system. Guide RNA (gRNA) and Cas9
were expressed using the px330 expression vector (Cong et al., 2013). The following gRNA target
sequence was used: 5’-GGAACCGACCATATTACAACAGG-3´ (recommended by the lab of Alexan-
der van der Bliek). Single clones were obtained by serial dilution after transfection and screened by
SDS-PAGE and immunoblotting.
qPCR
DNA extraction and cDNA synthesis were performed with established methods reported previously
(Issa et al., 2013). To specifically amplify and detect murine Yme1l1, human YME1L1, Hprt (Hypo-
xanthine-guanine phosphoribosyl-transferase, reference gene), and RPII (RNA polymerase II, refer-
ence gene) cDNA, we designed sets of primers and TaqMan probes specified in Supplementary file
1A using the GenScript real-time PCR (TaqMan) Primer Design online software (www.genscript.
com). qPCR and quantification was performed as described previously (Issa et al., 2013), and further
statistics were performed using the GraphPad Prism 5 Software (GraphPad Software Inc., La Jolla,
California).
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Western blot
Protein whole lysate extraction, fractionated mitochondrial and cytosolic protein extraction, and
Western blots were performed with established methods reported previously (Issa et al., 2013;
Potting et al., 2013). Antibodies are listed in Supplementary file 1B.
Isolation of a crude mitochondrial fraction
The protocol was adapted from (Vogel et al., 2005). Cells were harvested using trypsin and washed
three times in PBS to remove the trypsin. Subsequently, the cells were resuspended in 3 ml isotonic
Buffer (0,25 M Sucrose, 5 mM Tris-HCL pH 7,5, 1 mM EDTA and 0,1 mM PMSF). The cells were
opened with eight strokes by 2500 rpm using a potter homogenisator. Unbroken cells and nuclei
were removed by centrifugation at 600x g for 15 min at 4˚C. The supernatant was applied to another
centrifugation step at 10000x g for 25 min at 4˚C. The supernatant contains the cytoplasmic fraction
(C) whereas mitochondria are enriched in the pellet. The mitochondrial fraction (M) was washed two
times in isotonic buffer and afterwards applied to SDS Page.
Cell viability, apoptosis, and proliferation
Viability and proliferation of HAF were quantified using the Fluorimetric CellTiter-Blue Cell Viability
Assay (Promega, Madison, Wisconsin) and the colorimetric Cell Proliferation BrdU-ELISA (Roche
Diagnostics, Rotkreuz, Switzerland), respectively, according to the manufacturer´s instructions. Apo-
ptosis of HAF following treatment with staurosporine (Cell signaling, Cambridge, United Kingdom)
was determined through quantification of cleaved PARP protein levels on Western blots.
Mitochondrial respiratory chain enzyme activity
Mitochondrial respiratory chain enzyme activities were measured in skin fibroblasts according to
established procedures (Janssen et al., 2006; Smeitink et al., 2001). The values were expressed rel-
ative to the activity of Cytochrome C oxidase and/or Citrate synthase.
Overexpression of human YME1L1
Human wild type YME1L1 and mutant YME1L1R149W were stably expressed in Flp-In T-Rex HEK293T
cells (Life Technologies) under the control of a tetracycline-regulated promotor according to manu-
facturer´s instructions. HEK293T cells were cultured as described previously (Potting et al., 2013).
Transient transfection was performed using GeneJuice (EMD Millipore, Darmstadt, Germany)
according to manufacturer´s instruction.
Sucrose gradient density centrifugation
Cells were harvested and washed three times in PBS. Subsequently, the cells were resuspended in
isotonic buffer (0,25 M Sucrose, 5 mM Tris-HCL pH 7,5, 1 mM EDTA and 1X cOmplete, EDTA-free
Protease Inhibitor Cocktail [Sigma]). The cells were opened with 15 strokes by 1000 rpm using a Pot-
ter S homogenisator (Sartorius, Go¨ttingen, Germany). Unbroken cells and nuclei were removed by
centrifugation at 600x g for 5 min at 4˚C. The supernatant was applied to another centrifugation
step at 10000x g for 10 min at 4˚C. The mitochondrial-enriched membrane fraction (pellet) was re-
suspended in lysis buffer (270 mM sucrose, 100 mM KCl, 20 mM 20 mM MgCl2, 10 mM Tris/HCl, pH
7.5, and 1X cOmplete, EDTA-free Protease Inhibitor Cocktail) containing 6 g of digitonin per g of
protein at a concentration of 2.5 mg/ml for 20 min on ice. Supernatant from a clarifying centrifuga-
tion at 16,000 g for 10 min at 4˚C was directly applied to a 5–25% sucrose gradient prepared using
an automated gradient maker (Biocomp instruments, Fredericton, Canada) in 14x89mm Ultra-Clear
centrifuge tubes (Beckman Instruments, Brea, California). Ultracentrifugation was performed at
71,000 x g for 16 hr at 4˚C and 1.2 ml fractions (n=10) were collected by hand, precipitated by TCA
and subjected to SDS-PAGE.
Cell-free synthesis of YME1L1 and processing by purified MPP in vitro
The cell-free synthesis of (Baker et al., 2014) S-labeled precursor proteins of human wild type and
mutant YME1L1 was performed using the TNT Sp6 or Coupled Reticulocyte lysate system (Promega)
according to the manufacturer’s instructions. Radiolabeled wild type and mutant YME1L1 were incu-
bated in cleavage buffer (20 mM HEPES, pH 7,4, 50 mM NaCl2, 1 mM Zn Cl2, 1 mM ATP, 5 mM Mg
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Cl2) at 30˚C in the presence of absence of MPP as described previously (Nolden et al., 2005). Sam-
ples were analyzed by SDS-PAGE and autoradiography.
Immunocytochemistry
Immunocytochemistry was performed as described previously (Anand et al., 2014; Issa et al.,
2013). Antibodies are listed in Supplementary file 1B; DAPI was purchased from Sigma-Aldrich.
Mitochondrial network analysis
HAF, MEF, and ACF were stained with anti-TOMM20 antibody and DAPI (40,6-Diamidin-2-phenylin-
dol). Images were taken as described below and quantified in double-blind fashion into four catego-
ries: hyperfused, tubular, short tubules and fragmented mitochondrial network as previously
described (Anand et al., 2014). For the complementation experiments: co-transfection of 100 ng of
mitochondrially-targeted GFP (mito-GFP) along with 1 mg of either YME1L1 or YME1L1R149W was
performed, and GFP-positive fixed cells were scored for mitochondrial morphology.
Imaging
Fluorescently labeled fibroblasts were imaged with a fluorescent Olympus BX51 microscope using
the software Magnafire 2.1B Version 2001 (Olympus, Tokyo, Japan) and a Spinning Disc Microscopy
system (Carl Zeiss Microscopy, Oberkochen, Germany) with the ZEN 2012 Software, with an lsm5ex-
citer Zeiss confocal microscope (Carl Zeiss Microscopy). Analysis of overexpression experiment of
human wildtype and mutant YME1L1 was realized with an UltraVIEW VoX spinning disc Yokogawa
CSU-X1 confocal microscope (PerkinElmer, Waltham, Massachusetts) on a Nikon Ti microscope
equipped with a 60x (Apo TIRF 60x Oil N.A. 1.49) objective and camera (EMCCD C9100-50 Cam-
Link). Imaging of HeLa cells was performed using a Meta 510 confocal laser scanning microscope
(Carl Zeiss). All images were processed using Adobe Photoshop (Adobe Systems Inc., San Jose´, Cali-
fornia), Volocity (PerkinElmer), and ImageJ (National Institute of Health, USA).
Live-cell imaging
HAF were cultured on 35 mm Fluorodish Cell Culture Dishes (World Precision Instruments, Sarasota,
Florida) and incubated in pre-warmed medium containing 500 nM MitoTracker Green (Thermo Fisher
Scientific, Waltham, Massachusetts) 30 min prior to imaging. Live-cell imaging was performed in
fresh medium in the microscope incubation chamber (5% CO2, 37˚C) of a Zeiss Axio Observer with
Spinning Disc Technology Carl Zeiss Microscopy) for 7–10 min. Recordings were processed using
Adobe Photoshop (Adobe Systems Inc.) and Magix Video Maker Deluxe (Magix Software GmbH,
Berlin, Germany).
Electron microscopy (EM)
Fibroblasts and muscle biopsy specimen were prepared for TEM analysis and imaged as described
previously (Anand et al., 2014; Stenzel et al., 2015; Wakabayashi et al., 2009).
Statistical methods
All results are presented as mean ± SD, GraphPad Prism 5 software was used for all statistical analy-
ses, and the significance level was set at p<0.05. Differences between two groups were evaluated
by un-paired or paired Student’s t-test, while for multi-group comparisons, one-way ANOVA with
Tukey’s multiple-comparison test was used. For the mitochondrial fragmentation analysis
(Figure 3D), two-way ANOVA followed by the Tukey’s multiple-comparisons test was used. Sample
sizes, replicate numbers, and p-values are stated in the figure legends. Replicates are biological rep-
licates except for experiments illustrated in Figures 1H and 2B.
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